Immunovia Reports Third Quarter Interim Report January – September 2020
LUND, SWEDEN – Immunovia has today published third quarter interim report for January – September 2020. It is available on Immunovia’s website . “The most important event during Q3 was that we announced positive results from the IMMray™ PanCan-d verification study. The analysis from the verification study showed results in line with the previous commercial test model study (CTMS) and was the beginning of the last stage towards CLIA-CAP accreditation in the USA, the final blind validation study. Q3 started with a virtual presentation